Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, October 6, 2022
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
[ Thu, Oct 06th 2022
] - WOPRAI
Wed, October 5, 2022
[ Wed, Oct 05th 2022
] - WOPRAI
[ Wed, Oct 05th 2022
] - WOPRAI
Thomas Shrader Maintained (ABOS) at Strong Buy with Increased Target to $22 on, Oct 5th, 2022
Thomas Shrader of BTIG, Maintained "Acumen Pharmaceuticals, Inc." (ABOS) at Strong Buy with Increased Target from $15 to $22 on, Oct 5th, 2022.
Thomas has made no other calls on ABOS in the last 4 months.
There is 1 other peer that has a rating on ABOS. Out of the 1 peers that are also analyzing ABOS, 0 agree with Thomas's Rating of Hold.
This is the rating of the analyst that currently disagrees with Thomas
- Andrew Fein of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $15 on, Thursday, June 30th, 2022
